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AbstrACt
background Bispecific antibodies redirecting T cells to 
the tumor obtain increasing interest as potential cancer 
immunotherapy. ERY974, a full- length bispecific antibody 
targeting CD3ε on T cells and glypican 3 (GPC3) on tumors, 
has been in clinical development However, information on the 
influence of T cells on biodistribution of bispecific antibodies, 
like ERY974, is scarce. Here, we report the biodistribution 
and tumor targeting of zirconium-89 (89Zr) labeled ERY974 in 
mouse models using immuno- positron emission tomography 
(PET) imaging.
Methods To study both the role of GPC3 and CD3 on the 
biodistribution of [89Zr]Zr- N- suc- Df- ERY974, 89Zr- labeled 
control antibodies targeting CD3 and non- mammalian 
protein keyhole limpet hemocyanin (KLH) or KLH only 
were used. GPC3 dependent tumor targeting of [89Zr]
Zr- N- suc- Df- ERY974 was tested in xenograft models 
with different levels of GPC3 expression. In addition, CD3 
influence on biodistribution of [89Zr]Zr- N- suc- Df- ERY974 
was evaluated by comparing biodistribution between tumor- 
bearing immunodeficient mice and mice reconstituted with 
human immune cells using microPET imaging and ex vivo 
biodistribution. Ex vivo autoradiography was used to study 
deep tissue distribution.
results In tumor- bearing immunodeficient mice, [89Zr]Zr- 
N- suc- Df- ERY974 tumor uptake was GPC3 dependent and 
specific over [89Zr]Zr- N- suc- Df- KLH/CD3 and [89Zr]Zr- N- suc- 
Df- KLH/KLH. In mice engrafted with human immune cells, 
[89Zr]Zr- N- suc- Df- ERY974 specific tumor uptake was higher 
than in immunodeficient mice. Ex vivo autoradiography 
demonstrated a preferential distribution of [89Zr]Zr- N- suc- 
Df- ERY974 to T cell rich tumor tissue. Next to tumor, highest 
specific [89Zr]Zr- N- suc- Df- ERY974 uptake was observed in 
spleen and lymph nodes.
Conclusion [89Zr]Zr- N- suc- Df- ERY974 can potentially be 
used to study ERY974 biodistribution in patients to support 
drug development.
bACkground
Cancer treatment regimens increasingly 
contain monoclonal antibodies (mAb) with 
established mechanisms of action. These 
mAbs include drugs designed to block 
immune checkpoints, which are approved for 
multiple indications including melanoma, 
non- small- cell lung cancer and renal cell 
carcinoma.1 Unfortunately, not all patients 
with these tumor types treated benefit. 
Moreover, immunotherapy is still not effec-
tive in many tumor types. Therefore, novel 
approaches are exploited. This includes chal-
lenging approaches such as T cell redirecting 
bispecific antibodies, which target both T 
cells and tumor cells.2 By engaging T cells via 
CD3 and an antigen on tumor cells, T cells get 
activated to kill cancer cells.3 4 The activity of 
the anti- CD19/CD3 bispecific T cell engager 
blinatumomab in adult and pediatric patients 
with relapsed and refractory precursor B- cell 
acute lymphoblastic leukemia and with 
minimal residual disease resulted in the first 
approval of such an approach by the US 
Food and Drug administration and Euro-
pean Medicines Agency.5 For solid tumors, 
currently, several T cell redirecting bispecific 
antibodies are studied in clinical trials.4
ERY974 is a T cell redirecting bispecific anti-
body that targets human CD3 on T cells (Kd 
207 nM) and glypican 3 (GPC3; Kd 1.5 nM) on 
tumor cells.6 GPC3 is an oncofetal cell surface 
protein that is overexpressed in several tumor 
types while its expression is suppressed in 
healthy tissue.7 ERY974 is a fully humanized 
IgG4 antibody. It has preserved neonatal Fc 
receptor binding properties to allow extended 
circulating half- life by reducing lysosomal 
degradation, but lacks binding to Fcγ receptors 
(FcγR) to prevent GPC3- indepenent cytokine 
release by engaging FcγR and CD3. 6 Preclin-
ically, ERY974 inhibits growth of several solid 
tumor types in a mouse model with reconsti-
tuted human immune cells.6 ERY974 is in clin-
ical development.8
Molecular imaging could accelerate 
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biodistribution and target engagement.9 Recent inter-
esting preclinical data showed that distribution of a radio-
labeled bispecific antibody targeting CD3ε and human 
epidermal growth factor receptor 2 (HER2) is largely 
dependent on the affinity of the CD3ε arm of the anti-
body.10 It is difficult to predict the drug distribution of 
an engineered drug such as ERY974 that has two targets 
with different affinities. Studying ERY974’s biodistri-
bution might be informative for optimal treatment 
of patients. Prior to a clinical study, a preclinical study 
would allow studying additional experimental conditions 
by using multiple tumors and mouse models combined 
with different control antibodies. Therefore, to improve 
the understanding of ERY974’s behavior we aimed to 
characterize the impact of T cells on the biodistribu-
tion of ERY974 in a mouse model. We coupled ERY974 
to chelator N- succinyl desferal (N- suc- Df), followed by 
radiolabeling with the positron emission tomography 
(PET) isotope zirconium-89 (89Zr) to enable non- invasive 
molecular imaging of ERY974 to study its behavior in a 
tumor- bearing mouse model. To study both the role of 
GPC3 and CD3 on the biodistribution of [89Zr]Zr- N- suc- 
Df- ERY974, 89Zr- labeled control antibodies targeting CD3 
and non- mammalian protein keyhole limpet hemocy-
anin (KLH) or KLH only were used. CD3 influence was 
evaluated by comparing biodistribution between tumor- 
bearing immunodeficient mice and mice reconstituted 
with human immune cells. In addition, GPC3- dependent 
tumor targeting was tested in xenograft models with 
different levels of GPC3 expression. Ex vivo autoradiog-
raphy was used to study deep tissue distribution.
Methods
bispecific antibody constructs and cell lines
Bispecific antibody constructs ERY974 (IgG4), KLH/CD3 
(IgG1), KLH/KLH (IgG1) and bivalent GPC3 antibody 
were provided by Chugai Pharmaceutical. The disso-
ciation constants for the binding of ERY974 to human 
GPC3 and human CD3ε were 1.5±0.4 nM and 207±7, 
respectively. ERY974 was formulated in 150 mM arginine, 
20 mM histidine, 171 mM ʟ-aspartic acid and 0.52 mg/
mL poloxamer 188, pH 6.0. KLH/CD3 binds KLH and 
human CD3ε with similar affinity than ERY974, whereas 
KLH/KLH binds KLH only. The molecular weight of the 
antibodies is approximately 146 kDa and all were engi-
neered to abolish FcγR binding.6
The human hepatocellular carcinoma cell line HepG2 
(GPC3+), human ovarian clear cell carcinoma cell line 
TOV- 21G (GPC3+) and human hepatocellular carci-
noma cell line SK- HEP-1 (GPC3-) were used. All cell lines 
were obtained from American Type Culture Collection 
and confirmed to be negative for microbial contamina-
tion. Cell lines were authenticated by BaseClear using 
short tandem repeat profiling. This was repeated once 
a cell line has been passaged for more than 6 months 
after previous short tandem profiling. HepG2 cells 
were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Invitrogen), TOV- 21G in a 1:1 mixture of Ham’s 
F12/DMEM, SK- HEP-1 in DMEM with high glucose 
(Invitrogen) supplemented with 10% fetal bovine serum 
(Bodinco BV). All cells were cultured under humidified 
conditions at 37°C with 5% CO2.
Animal experiments
We used female NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac 
(NOG; median body weight 22 g with IQR of 21–23 g) 
mice (Taconic) or female humanized NOG (huNOG; 22 
g with IQR 20–23) mice which were engrafted with human 
CD34 +hematopoietic stem cells (Taconic11). Human 
leukocyte reconstitution was checked by flow cytometry 
at 16 weeks postengraftment and CD3+ engraftment was 
similar between experimental groups (online supplemen-
tary figure S1). Mice were housed per five mice in specific 
pathogen- free cages, with cage enrichment, on a 12- hour 
day/night cycle, and ad libitum access to food and water. 
Mice were allowed to acclimate for at least 1 week on 
arrival. At approximately 25 weeks of age 10×106 HepG2, 
TOV- 21G or SK- HEP-1 cells in 1:1 ratio of medium and 
Matrigel (BD Biosciences; 0.3 mL) were subcutaneously 
injected for xenograft development. Tumor growth was 
assessed by caliper measurements and body weight was 
monitored twice weekly. Retro- orbital tracer injection 
(for description of tracer manufacturing see online 
supplementary additional methods) was performed 
when tumors reached a size of 200 mm3. This was reached 
for TOV- 21G in 14 days and for HepG2 and SK- HEP-1 
in 24 days. Anesthesia during microPET scanning was 
performed with isoflurane/oxygen inhalation (5% induc-
tion, 2.5% maintenance). Details regarding number of 
animals, microPET scans and time of biodistribution are 
included in the figure legends.
MicroPet scanning and ex vivo biodistribution
All microPET scans were performed in a Focus 200 rodent 
scanner (CTI Siemens). Mice were kept warm on heating 
mats. A transmission scan of 515 s was obtained using a 
57Co point source for tissue attenuation. The reconstruc-
tion of microPET scans was performed as previously 
described.12 After reconstruction, images were interpo-
lated with trilinear interpolation using PMOD software 
(V.3.7, PMOD Technologies). Coronal microPET images 
or maximal intensity projection images were used for 
display. Volumes of interest (VOI) of the whole tumor 
were drawn based on biodistribution tumor weight. For 
the heart, a 92 mm3 VOI in the coronal plane was drawn. 
VOIs were subsequently quantified. Data are expressed as 
the mean standardized uptake value (SUVmean).
For all ex vivo biodistribution studies, tumor, whole 
blood and organs of interest were collected and weighed. 
Samples together with tracer standards were counted in a 
calibrated well- type g- counter (LKB Instruments). Uptake 
is expressed as the percentage injected dose per gram of 
tissue (%ID/g).
To determine binding to peripheral blood mononu-
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using SepMate-15 tubes (STEMCELL Technologies) with 
Ficoll- Paque PLUS (GE Healthcare). Buffy coat frac-
tion was washed twice using phosphate buffered saline 
(PBS; 140 mM/L NaCl, 9 mM/L Na2HPO4, 1.3 mM/L 
NaH2PO4, pH 7.4, UMCG) with 2% fetal calf serum. 
Radioactivity was counted of whole blood and PBMCs.
ex vivo autoradiography and immunohistochemistry
Tumors, spleen or mesenteric lymph nodes were fixed in 
formalin overnight, followed by paraffin embedding. Four 
µm sections were subsequently exposed overnight to a 
phosphor screen (PerkinElmer) in an X- ray cassette. Signal 
was detected with a Cyclone Storage Phosphor System 
(PerkinElmer). Slides used for ex vivo autoradiography 
were deparaffinized then stained with H&E and digitalized 
with NanoZoomer and NDP software (Hamamatsu). Subse-
quent slides were stained for GPC3 (tumor only) and CD3ε 
(online supplementary additional methods).
For ex vivo tissue, autoradiography quantification of 
tumor sections, regions of interest (ROIs) were drawn 
for tumor cells and stromal regions based on H&E. ROIs 
were exported to ImageJ (National Institutes of Health, 
USA), rescaled for ex vivo autoradiography and ROIs were 
measured.
For tumor lysate and plasma analysis, samples were 
heated for 10 min at 70°C and 40 µg protein of tumor 
lysates or mouse plasma from three mice, tracer alone as 
positive control were loaded on mini- PROTEAN TGX 
Precast Gels (Bio- Rad). Gels were exposed overnight to 
phosphor imaging screens (PerkinElmer) in X- ray cassettes 
and analyzed using a Cyclone Storage Phosphor System 
(PerkinElmer).
statistical analysis
Statistical analyses were performed using GraphPad Prims 
V. 7.02. Unless otherwise stated, data are presented as 
median±IQR. Mann- Whitney U test was performed to test 
differences between two groups. Bonferroni correction 
was applied when more than two groups were compared. 
P values≤0.05 were considered significant.
results
In vitro characterization of [89Zr]Zr-n-suc-df-erY974 and 
control tracers
We successfully radiolabeled ERY974 and control anti-
bodies with 89Zr with a molar activity (Am) of 72.8 MBq/
nmol at the end of synthesis. Radiochemical purity 
exceeded 95% after labeling and high molecular weight 
species were below 5%. In vitro, the intermediate N- suc- 
Df- ERY974 binds GPC3 and CD3ε similarly to unconju-
gated ERY974 in an ELISA- based binding assay, indicating 
preserved binding to both targets (online supplementary 
figure S2A and B). The T cell activation potency of N- suc- 
Df- ERY974 was not affected, being similar to unmodified 
ERY974 (online supplementary figure S2C). This in vitro 
data demonstrate that N- suc- Df- ERY974 can be used as 
a surrogate for ERY974 to study its biodistribution. In 
GPC3- positive HepG2 tumor cells, 12.9%±3.2% [89Zr]
Zr- N- suc- Df- ERY974 internalized after 4 hours (online 
supplementary figure S2D). Control tracers KLH/CD3 
and KLH/KLH did not bind to GPC3 and only [89Zr]
Zr- N- suc- Df- KLH/CD3 bound CD3ε (online supplemen-
tary figure S2E and F).
tumor xenograft accumulation of [89Zr]Zr-n-suc-df-erY974 in 
time in immunodeficient nog mice
The optimal time point for microPET imaging with 
[89Zr]Zr- N- suc- Df- ERY974 providing the highest tumor- 
to- blood ratio in HepG2 xenograft bearing immunodefi-
cient NOG mice was 168 hours after injection. MicroPET 
images revealed clear tumor uptake of [89Zr]Zr- N- suc- 
Df- ERY974 already at 24 hours after intravenous injection 
(figure 1A). After tracer injection over time, the blood 
levels decreased and tumor levels increased up to 120 
hours, resulting in a maximal tumor- to- blood ratio of 
2.2±0.3 at 168 hours (figure 1B,C).
biodistribution and tumor uptake of [89Zr]Zr-n-suc-df-erY974 
in immunodeficient nog mice bearing tumor xenografts with 
different gPC3 expression
In both GPC3 positive tumor models, HepG2 (GPC3 high) 
and TOV- 21G (GPC3 low; online supplementary figure 
S3A), [89Zr]Zr- N- suc- Df- ERY974 tumor uptake was visualized 
with microPET, whereas GPC3- negative xenograft SK- HEP-1 
revealed lower uptake (figure 2A,B; online supplementary 
figure S3A). Ex vivo biodistribution at 168 hours after tracer 
administration confirmed GPC3- dependent uptake of 
[89Zr]Zr- N- suc- Df- ERY974, with higher uptake in TOV- 21G 
xenografts and lower uptake in SK- HEP-1 compared with 
HepG2 xenografts (figure 2C). [89Zr]Zr- N- suc- Df- ERY974 
tumor- to- blood ratio of was highest in HepG2 tumors 
(figure 2D). Ex vivo autoradiography of tumor tissue at 168 
hours after tracer administration, showed [89Zr]Zr- N- suc- 
Df- ERY974 presence mainly confined to GPC3 expressing 
tumor tissue areas of HepG2 and TOV- 21G xenografts 
(online supplementary figure S3A). In contrast, GPC3 
negative SK- HEP-1 xenografts showed predominantly 89Zr 
localization in non- tumor tissue (online supplementary 
figure S3A). In all xenograft models, 89Zr- uptake reflected 
intact but also fragments of [89Zr]Zr- N- suc- Df- ERY974 in 
tumor lysates and blood plasma (online supplementary 
figure S3B).
[89Zr]Zr- N- suc- Df- ERY974 biodistribution demon-
strated highest physiological uptake in spleen followed by 
liver, lung and kidney at 168 hours after tracer admin-
istration (figure 2C). [89Zr]Zr- N- suc- Df- ERY974 blood 
levels in TOV- 21G xenograft bearing mice were higher 
and liver uptake was lower, compared with HepG2 xeno-
graft bearing mice (figure 2C).
spleen and bone marrow uptake of [89Zr]Zr-n-suc-df-erY974 
in immunodeficient nog mice
[89Zr]Zr- N- suc- Df- ERY974 uptake in the spleen was ±18 
%ID/g in all tumor- bearing NOG mice and thereby 
the highest uptake observed compared with any organ 
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Figure 1 [89Zr]Zr- N- suc- Df- ERY974 distribution in time. (A) Maximal intensity projection images of [89Zr]Zr- N- suc- Df- ERY974 
in HepG2 tumor (white dotted circle) bearing NOG mice at 24 hours, 72 hours, 120 hours and 168 hours post 10 µg [89Zr]Zr- N- 
suc- Df- ERY974 injection. (B) Quantification of tumor and blood pool (n=6). data shown as median SUVmean and IQR. (C) Tumor- 
to- blood ratio based on SUVmean. Data shown as median tumor- to- blood ratio and IQR. Cr, cranial; Ca, caudal; H, heart; L, liver; 
SUVmean, standardised uptake value; T, tumor.
NOD.Cg- PrkdcscidIl2rgtm1Wjl (NSG) mice,13 spleen uptake in 
our experiment was also influenced by FcγR- modification 
of the mAb, with lower spleen uptake for FcγR- silenced 
mAbs (online supplementary figure S4A and B). In 
addition, with high radioactive dose spleens of our mice 
shrunk in time and aplasia was observed 168 hours after 
injection with median weight of 10 mg IQR 8–12 at 
higher radioactive dose versus24 mg IQR 20–33 at a lower 
radioactive dose (online supplementary figure S4C- G13). 
Spleen uptake is also affected by mouse strain, as our 
less immunodeficient nude (BALB/cOlaHsd-Foxn1nu) 
mice demonstrated lower relative spleen uptake of [89Zr]
Zr- N- suc- Df- ERY974 than NOG mice (online supplemen-
tary figure S4H), similarly described for an 89Zr- labeled 
antibody targeting delta- like protein 3.14 Interestingly, 
absolute spleen uptake of [89Zr]Zr- N- suc- Df- ERY974 was 
higher in nude mice (online supplementary figure S4I 
and J). Relative bone marrow uptake of [89Zr]Zr- N- suc- 
Df- ERY974 was also lower in nude mice than NOG mice, 
while cortical bone uptake was similar (online supple-
mentary figure S4K). In summary, a relative high spleen 
uptake of 89Zr- mAb in NOG mice is related to host and 
mAb characteristics and mediated by radiation dose, as 
demonstrated earlier in NSG mice.13
Influence of erY974 protein dose on [89Zr]Zr-n-suc-df-
erY974 tumor xenograft uptake and biodistribution in 
immunodeficient nog mice
To test the effect of protein dose on [89Zr]Zr- N- suc- 
Df- ERY974 tumor targeting and biodistribution, 10 µg 
[89Zr]Zr- N- suc- Df- ERY974 was supplemented with a dose of 
unlabeled ERY974. A 200- fold excess of unlabeled protein 
(2 mg) was unable to reduce HepG2 tumor uptake of 
[89Zr]Zr- N- suc- Df- ERY974 and even increased uptake in 
HepG2 xenografts at 168 hours after injection (online 
supplementary figure S5A). However, this dose did lower 
[89Zr]Zr- N- suc- Df- ERY974 liver uptake while [89Zr]Zr- N- 
suc- Df- ERY974 blood levels remained unchanged (online 
supplementary figure S5B and D). HepG2 xenograft 
uptake of [89Zr]Zr- N- suc- Df- ERY974 could also not be 
blocked with 100- fold excess of unlabeled bivalent GPC3 
mAb, but resulted in increased blood levels leading to a 
lower tumor- to- blood ratio (online supplementary figure 
S5B and C). In TOV21G xenografts, which express less 
GPC3, data suggests that 2000 µg total protein dose 
ERY974 reduced, although non- significant, tumor uptake 
of [89Zr]Zr- N- suc- Df- ERY974 with 62.1% (online supple-
mentary figure S5A; P = 0.07).
specificity of hepg2 xenograft uptake of [89Zr]Zr-n-suc-df-
erY974 in immunodeficient nog mice
To demonstrate that tumor uptake is GPC3 dependent, 
control tracers [89Zr]Zr- N- suc- Df- KLH/CD3 and [89Zr]
Zr- N- suc- Df- KLH/KLH were administered to HepG2 
bearing immunodeficient NOG mice. At 168 hours after 
injection, tumor uptake on microPET images of [89Zr]Zr- N- 
suc- Df- ERY974 was better visible than of [89Zr]Zr- N- suc- 
Df- KLH/CD3 or [89Zr]Zr- N- suc- Df- KLH/KLH (figure 3A). 
Scan quantification of tumor uptake showed less tumor 
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Figure 2 [89Zr]Zr- N- suc- Df- ERY974 distribution in immunodeficient NOG mice bearing different tumor xenografts. (A) Coronal 
microPET images (upper panel) and maximal intensity projection (MIP) images (lower panel) of NOG mice bearing HepG2, 
TOV- 21G or SK- HEP-1 xenografts (white circle) 168 hours post 10 µg [89Zr]Zr- N- suc- Df- ERY974 injection. (B) Quantification 
of HepG2 (n=6), TOV- 21G (n=6) or SK- HEP-1 (n=6) uptake of [89Zr]Zr- N- suc- Df- ERY974 (upper graph) and corresponding 
blood pool uptake (lower graph) at 72 hours and 168 hours post- tracer injection. Data shown as median SUVmean and IQR. (C) 
Ex vivo biodistribution of [89Zr]Zr- N- suc- Df- ERY974 168 hours post- tracer administration. Data are expressed as median with 
IQR. *P≤0.05; **P≤0.01; ***P≤0.001 (Mann- Whitney U). (D) Tumor- to- blood ratio based on ex vivo biodistribution of C. Data are 
expressed as median with IQR. **P≤0.01; ***P≤0.001 (Mann- Whitney U). Cr, cranial; Ca, caudal; H, heart; L, liver; PET, positron 
emission tomography; SUVmean, standardised uptake value; T, tumor; 
89Zr, zirconium-89.
Zr- N- suc- Df- KLH/KLH, with a median SUVmean of 0.75 with 
an IQR of 0.59–0.91 and 1.08 (IQR 0.71–1.82) vs 2.91 (IQR 
2.74–3.03) for [89Zr]Zr- N- suc- Df- KLH/CD3, [89Zr]Zr- N- suc- 
Df- KLH/KLH and [89Zr]Zr- N- suc- Df- ERY974, respectively 
(figure 3B). Furthermore, ex vivo biodistribution results 
at 168 hours after injection supported the findings with 
the microPET images. This also revealed additional differ-
ences in tracer distribution such as lower blood levels for 
[89Zr]Zr- N- suc- Df- KLH/CD3 and higher for [89Zr]Zr- N- 
suc- Df- KLH/KLH compared with [89Zr]Zr- N- suc- Df- N- suc- 
Df- ERY974 (figure 3C). Similarly, liver uptake was higher 
for [89Zr]Zr- N- suc- Df- KLH/KLH and lower for [89Zr]Zr- N- 
suc- Df- KLH/CD3 compared with [89Zr]Zr- N- suc- Df- ERY974 
(figure 3C). [89Zr]Zr- N- suc- Df- ERY974, [89Zr]Zr- N- suc- 
Df- KLH/CD3 and [89Zr]Zr- N- suc- Df- KLH/KLH all showed 
relatively high distribution to spleens of immunodeficient 
NOG mice (figure 3C).
biodistribution and tumor xenograft uptake of [89Zr]Zr-n-suc-
df-erY974 in nog mice engrafted with human immune cells
To study the biodistribution and tumor- targeting prop-
erties of [89Zr]Zr- N- suc- Df- ERY974 with additional avail-
ability of human CD3 on T cells, HepG2 tumor- bearing 
huNOG mice reconstituted with human immune cells 
were studied. Compared with HepG2 xenograft bearing 
NOG mice, [89Zr]Zr- N- suc- Df- ERY974 showed increased 
tumor uptake in HepG2 bearing huNOG mice with 
median SUVmean of 7.3 (IQR 4.3–9.3) at 168 hours after 
injection (figure 4A,B; online supplementary figure S6). 
Compared with [89Zr]Zr- N- suc- Df- ERY974, control tracers 
[89Zr]Zr- N- suc- Df- KLH/CD3 and KLH/KLH adminis-
tered to huNOG mice were taken up lower by the tumor 
with a median SUVmean of 0.6 (IQR 0.3–0.7) and 1.6 (IQR 
1.5–1.9), respectively (figure 4B).
Apart from tumor uptake, highest organ uptake 
for [89Zr]Zr- N- suc- Df- ER974 was observed for spleen, 
followed by mesenteric lymph nodes (MLN) and liver 
(figure 4C). Both CD3 targeting molecules [89Zr]Zr- N- 
suc- Df- ERY974 and [89Zr]Zr- N- suc- Df- KLH/CD3 revealed 
twofold to threefold higher uptake in lymphoid organs 
such as spleen and MLN than [89Zr]Zr- N- suc- Df- KLH/
KLH (figure 4C). Median spleen weight of huNOG mice, 
as determined by biodistribution at 7 days after tracer 
administration, was 26 mg (IQR 22–32) and not different 
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Figure 3 Distribution of [89Zr]Zr- N- suc- Df- ERY974 and control tracers in HepG2 xenograft bearing immunodeficient NOG mice 
(A) coronal microPET images of HepG2 (white dotted circle) bearing NOG mice injected with 10 µg [89Zr]Zr- N- suc- Df- ERY974, 
[89Zr]Zr- N- suc- Df- KLH/CD3 or [89Zr]Zr- N- suc- Df- KLH/KLH 168 hours post tracer injection. (B) Quantification of [89Zr]Zr- N- suc- 
Df- ERY974 (n=6), [89Zr]Zr- N- suc- Df- KLH/CD3 (n=5) or [89Zr]Zr- N- suc- Df- KLH/KLH (n=6) uptake in HepG2 tumor and blood pool. 
Data shown as median SUVmean and IQR. *P≤0.05; **P≤0.01 (Mann- Whitney U). (C) Ex vivo biodistribution of [
89Zr]Zr- N- suc- Df- 
ERY974, [89Zr]Zr- N- suc- Df- KLH/CD3 and [89Zr]Zr- N- suc- Df- KLH/KLH 168 hours post- tracer administration. Data are expressed 
as median with IQR. *P≤0.05; **P≤0.01; ***P≤0.001 (Mann- Whitney U). Cr, cranial; Ca, caudal; KLH, keyhole limpet hemocyanin; 
L, liver; PET, positron emission tomography; SUVmean, standardised uptake value; T, tumor; 
89Zr, zirconium-89.
CD3 showed higher blood levels in huNOG mice than 
in NOG mice at 168 hours after tracer administration 
(online supplementary figure S6B). Furthermore, higher 
binding of [89Zr]Zr- N- suc- Df- ERY974 and [89Zr]Zr- N- 
suc- Df- KLH/CD3 than [89Zr]Zr- N- suc- Df- KLH/KLH to 
peripheral blood mononuclear cells of huNOG mice was 
observed (online supplementary figure S7). Collectively, 
[89Zr]Zr- N- suc- Df- ERY974 demonstrated increased tumor 
uptake between NOG and huNOG mice and CD3 specific 
uptake in lymphoid tissues of huNOG mice.
ex vivo autoradiography of tumor and lymphoid tissues of 
hunog mice
We performed ex vivo autoradiography and evaluated T 
cell infiltration to determine microscopic colocalization of 
tracers in tumors and lymphoid tissues of mice engrafted 
with human immune cells. In HepG2 tumors, [89Zr]Zr- N- 
suc- Df- ERY974 gave higher radioactive signal in stromal 
regions with high CD3+ T cells infiltrate than tumor nests 
(figure 5A–C). Total radioactivity signal measured by ex 
vivo autoradiography correlated well with %ID/g of the 
individual tumor (R2=0.7178; figure 5C). For lymphoid 
organs spleen and mesenteric lymph nodes, both CD3- 
targeting tracers located to regions with human CD3+ 
cells (figure 5E,F). [89Zr]Zr- N- suc- Df- KLH/KLH distrib-
uted independent of CD3+ cells (figure 5G).
The T cell infiltration of HepG2 xenografts observed 
in huNOG mice injected with[89Zr]Zr- N- suc- Df- ERY974 
was not observed following injection of [89Zr]Zr- N- suc- 
Df- KLH/CD3 and [89Zr]Zr- N- suc- Df- KLH/KLH, in both 
tumor and stromal regions (online supplementary figure 
S8A). Quantification of CD3+ T cells confirmed less T 
cell infiltration with 41 (IQR 21–303) CD3+ cells/mm2 
for [89Zr]Zr- N- suc- Df- KLH/CD3, 50 (IQR 22–85) CD3+ 
cells/mm2 for [89Zr]Zr- N- suc- Df- KLH/KLH and 707 (IQR 
670–1133) CD3+ cells/mm2 for [89Zr]Zr- N- suc- Df- ERY974, 
(online supplementary figure S8B). This difference might 
be explained by the pharmacological effect of 10 µg of 
[89Zr]Zr- N- suc- Df- ERY974 that leads to immune cell infil-
tration as demonstrated earlier,6 which effect is absent 
for [89Zr]Zr- N- suc- Df- KLH/CD3 and [89Zr]Zr- N- suc- 
Df- KLH/KLH. Tumor weight at 7 days after [89Zr]Zr- N- 
suc- Df- ERY974 administration was lower compared with 
[89Zr]Zr- N- suc- Df- KLH/CD3 or [89Zr]Zr- N- suc- Df- KLH/
KLH, with median weight of 238 mg (IQR 194–367) vs 
676 mg (IQR 479–807), respectively (p<0.05; data not 
shown). We therefore studied the distribution of [89Zr]
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Figure 4 Distribution of [89Zr]Zr- N- suc- Df- ERY974 and control tracers in HepG2 xenograft bearing humanized NOG mice 
(A) coronal microPET images of HepG2 (white dotted circle) bearing humanized NOG mice reconstituted with human immune 
cells injected with 10 µg [89Zr]Zr- N- suc- Df- ERY974, [89Zr]Zr- N- suc- Df- KLH/CD3 or [89Zr]Zr- N- suc- Df- KLH/KLH 72 hours and 
168 hours post- tracer injection. (B) Quantification of [89Zr]Zr- N- suc- Df- ERY974 (n=5), [89Zr]Zr- N- suc- Df- KLH/CD3 (n=4) or [89Zr]
Zr- N- suc- Df- KLH/KLH (n=6) uptake in HepG2 tumor and blood pool. Data shown as median SUVmean and IQR. (C) Ex vivo 
biodistribution of [89Zr]Zr- N- suc- Df- ERY974, [89Zr]Zr- N- suc- Df- KLH/CD3 and [89Zr]Zr- N- suc- Df- KLH/KLH 168 hours post- tracer 
administration. Data are expressed as median with IQR. *P≤0.05 (Mann- Whitney U). Cr, cranial; Ca, caudal; KLH, keyhole limpet 
hemocyanin; L, liver; MLN, mesenteric lymph node; PET, positron emission tomography; SUVmean, standardised uptake value; T, 
tumor; 89Zr, zirconium-89.
KLH in a HepG2 bearing huNOG mice co- injected with 
10 µg of N- suc- Df- ERY974. N- suc- Df- ERY974 coinjection 
resulted in strong CD3+ T cell infiltration in HepG2 
tumors of huNOG administered with [89Zr]Zr- N- suc- 
Df- KLH/CD3 or [89Zr]Zr- N- suc- Df- KLH/KLH, in similar 
range as [89Zr]Zr- N- suc- Df- ERY974 (online supplemen-
tary figure S9). ERY974 coinjection did not result in 
major differences in physiological organ uptake of [89Zr]
Zr- N- suc- Df- KLH/CD3 or [89Zr]Zr- N- suc- Df- KLH/KLH, 
but did increase tumor uptake from 3.4 (IQR 2.0–3.6) to 
10.0 (IQR 9.9–16.3) and from 6.1 (IQR 4.0–7.9) to 16.6 
%ID/g (IQR 10.4–23.8) for [89Zr]Zr- N- suc- Df- KLH/CD3 
and [89Zr]Zr- N- suc- Df- KLH/KLH, respectively (online 
supplementary figure S6).
dIsCussIon
This is the first study using molecular imaging to study the 
influence of T cells on the distribution and tumor uptake 
of the therapeutic T cell redirecting bispecific antibody 
ERY974 targeting CD3ε and GPC3. [89Zr]Zr- N- suc- 
Df- ERY974 tumor uptake was higher in human immune 
cell engrafted mice than in immunodeficient mice, and 
localized in the T cell infiltrated stromal regions. Next to 
tumor uptake, second highest [89Zr]Zr- N- suc- Df- ERY974 
uptake was found in CD3+ lymphoid tissues such as spleen 
and mesenteric lymph nodes, followed by liver.
The role of T cells on the biodistribution of T cell 
redirecting antibodies is poorly understood since its 
biodistribution is mainly studied in immunocompro-
mised mice, which prohibits to study the influence of 
the CD3 arm of the bispecific antibody.12 15 The current 
study shows that in the presence of T cells, specific phys-
iological uptake is observed in CD3+ T cell containing 
organs such as spleen and lymph nodes. In contrast, 
for antibodies targeting tumor cell and growth factors 
highest physiological uptake is usually observed in liver.16 
However, a recent clinical molecular imaging study with 
the immune checkpoint inhibitor atezolizumab demon-
strated that lymphoid tissues can also be an important 
compartment for drug biodistribution.17 For example, 
[89Zr]Zr- N- suc- Df- atezolizumab, targeting the immune 
checkpoint programmed death- ligand 1, showed highest 
physiological uptake in spleen of patients with cancer. 
Furthermore, in the majority of the patients molecular 
PET imaging with [89Zr]Zr- N- suc- Df- atezolizumab was 
able to detect healthy lymph nodes.
The role of the CD3ε directed arm of a bispecific T 
cell redirecting antibody will be impacted by its affinity. 
An interesting study evaluated the impact of a CD3ε 
binding arm on the biodistribution of T cell redirecting 
antibodies in a human CD3ε transgenic mouse model 
using a HER2/CD3 bispecific antibody with different 
affinities for CD3ε.10 A low affinity for CD3ε (CD3εL), 
which was considered 50 nM, did not redirect a non- 
tumor targeting bispecific antibody to lymphoid organs. 
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Figure 5 Intratumoral distribution of [89Zr]Zr- N- suc- Df- ERY974 in HepG2 bearing huNOG mice (A) autoradiography (first 
panel) of [89Zr]Zr- N- suc- Df- ERY974 in HepG2 bearing huNOG mice with subsequent slides stained for human CD3 (second 
panel), (H&E; third panel) and human GPC3 (fourth panel). Scale bar length represents 5 mm for whole tissue and 500 µm for 
magnified tissue. (B) ROI drawing of tumor cells and stromal regions based on H&E staining (upper panel) and the overlay 
on autoradiography (lower panel). Scale bar length represents 2.5 mm. (C) Quantification of tumor and stromal regions on 
autoradiography. Circle and square with an inner dot represent the quantification of the tumor and stroma shown in (B). 
Checked circle and square represents the quantification of tumor and stroma depicted in (A). (D) Mean total tumor value on 
autoradiography correlated with the %ID/g of the same tumor. (E) Autoradiography (top panel), CD3 immunohistochemistry 
(middle panel) and H&E staining (bottom panel) of spleen and mesenteric lymph node (MLN) of huNOG mice injected with [89Zr]
Zr- N- suc- Df- ERY974. Autoradiography and H&E were performed on the same slide. scale bar length represents 2.5 mm. (F) 
Autoradiography (top panel), CD3 immunohistochemistry (middle panel) H&E staining (bottom panel) of spleen and MLN of 
huNOG mice injected with [89Zr]Zr- N- suc- Df- KLH/CD3. Scale bar length represents 2.5 mm. (G) Autoradiography (top panel), 
CD3 immunohistochemistry (middle panel) and H&E staining (bottom panel) of spleen and MLN of huNOG mice injected with 
[89Zr]Zr- N- suc- Df- KLH/KLH. Scale bar length represents 2.5 mm. GPC3, glypican 3; huNOG, humanised NOG; KLH, keyhole 
limpet hemocyanin; 89Zr, zirconium-89.
nM) affinity to CD3ε showed extensive distribution to 
lymphoid tissues such as spleen and lymph nodes, which 
could be blocked by a 100- fold excess of unlabeled CD3 
single arm antibody. For the tumor targeting of HER2/
CD3ε antibody, the antibodies with high affinity for CD3ε 
lowered tumor targeting compared with HER2/CD3εL. 
Tumor uptake of HER2/CD3εL could only be reduced 
by an excess of unlabeled HER2 single arm antibody and 
not by CD3 single arm antibody, suggesting limited effect 
of CD3ε on tumor uptake. [89Zr]Zr- N- suc- Df- ERY974 and 
[89Zr]Zr- N- suc- Df- KLH/CD3, with a submicromolar (207 
nM) affinity for CD3ε, have a lower affinity compared with 
the CD3εL. Despite the lower affinity for CD3ε, specific 
uptake in spleen and lymph nodes was shown for [89Zr]
Zr- N- suc- Df- ERY974 and [89Zr]Zr- N- suc- Df- KLH/CD3 in 
huNOG mice. Moreover, tumor uptake of [89Zr]Zr- N- suc- 
Df- ERY974 was threefold higher compared with uptake in 
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pharmacological active dose of [89Zr]Zr- N- suc- Df- ERY9746 
tumors got heavily infiltrated with T cells, both in intratu-
moral and in stromal regions. Autoradiography illustrated 
that [89Zr]Zr- N- suc- Df- ERY974 was predominantly local-
ized to T cell infiltrated stromal regions. The T cell infil-
tration of the tumor might be due to local proliferation 
of resident T cells on activation by the bispecific antibody 
as demonstrated in earlier studies6 18 19 or by bispecific 
antibody mediated migration. In our study [89Zr]Zr- N- 
suc- Df- ERY974 specifically bound to peripheral blood 
cells. On encountering the tumor, [89Zr]Zr- N- suc- Df- 
ERY974- bound T cells might get into the tumor due to 
GPC3 expression, resulting in increased tumorous T cell 
infiltration and ERY974 uptake. An immunoPET study 
in a CD3 transgenic mouse model bearing a mucin16 
(MUC16) positive xenograft with an 89Zr- labeled full- 
length bispecific T cell redirecting antibody REGN4018 
targeting MUC16 and CD3ε also demonstrated tumor 
and secondary lymphoid organ targeting.20 However, 
affinities for both targets were not disclosed and tumor 
uptake of 89Zr- labeled REGN4018 was not compared with 
control tracers or tumor- bearing wild type mice.
As T cell redirecting bispecific antibodies have not 
shown antitumor effects in patients with solid tumors 
yet, it is key to better understand its behavior to support 
drug development. Clinical information regarding the 
biodistribution of T cell redirecting antibodies could 
provide additional insight in tumor targeting properties 
and off- target distribution. However, clinical data are 
strikingly limited. The distribution of an 89Zr- labeled 54 
kDa bispecific T cell engager AMG211 targeting CD3ε 
(affinity 310 nM) and carcinoembryonic antigen (affinity 
5.5 nM) was studied in a feasibility study in nine patients 
with advanced gastrointestinal adenocarcinomas.21 [89Zr]
Zr- N- suc- Df- AMG211 clearly accumulated in spleen and 
bone marrow, both CD3- rich tissues. Uptake of [89Zr]
Zr- N- suc- Df- AMG211 in tumor lesions was highly hetero-
geneous within and between patients. For [89Zr]Zr- N- suc- 
Df- ERY974, evaluation in a clinical trial would be helpful 
to further understand ERY974’s behavior and tumor 
targeting properties. Whole body non- invasive imaging of 
[89Zr]Zr- N- suc- Df- ERY974 might help to inform potential 
target- related drug impact in vivo including off- tumor/
on- target or off- target uptake. Information regarding 
distribution of [89Zr]Zr- N- suc- Df- ERY974 at baseline and 
during ERY974 treatment, could further aid in the drug 
development of ERY974. Biopsies would allow to correlate 
PET signal with multiple parameters such as tumorous T 
cell infiltration and GPC3 protein expression. Further-
more, biopsies combined with tissue autoradiography 
could provide information regarding 89Zr distribution in 
both stroma and tumor areas, as shown in this preclinical 
study. With the potency of T cell redirecting bispecific 
antibodies, radiolabeling a low protein dose would be a 
challenge in a clinical study. In the end, results from such 
a clinical study could support rational future trial design.
Although the engraftment of human immune cells 
allowed us to study the influence of T cells on the 
biodistribution of [89Zr]Zr- N- suc- Df- ERY974, the mouse 
model used in this study does not fully recapitulate the 
human environment. The reconstituted immune cells 
that were present in the mice in this study did home 
to lymphoid tissues and were able to infiltrate xeno-
grafts, leading to CD3 specific uptake of [89Zr]Zr- N- suc- 
Df- ERY974 and [89Zr]Zr- N- suc- Df- KLH/CD3. Uptake of 
[89Zr]Zr- N- suc- Df- ERY974 found in lymphoid organs of 
these mice needs to be interpreted and potentially trans-
lated with caution. We observed CD3 independent uptake 
of [89Zr]Zr- N- suc- Df- ERY974 in spleens due to the genetic 
background of the mice used in this study. This effect 
was mediated by radioactivity- related spleen aplasia and 
mAb affinity for FcγR. The non- specific spleen uptake 
was observed earlier in SCID mice,22 NOG mice23 and 
NSG mice.14 In a more comprehensive study, the role of 
radioactivity, mouse strain and FcγR affinity of the mAb 
confirmed the underlying mechanism.13 Besides the lack 
of a fully intact and functional human immune system, 
lack of cross- reactivity toward GPC3 did not allow us to 
study the non- tumor targeting of ERY974 to organs with 
physiological GPC3 expression and is therefore a limita-
tion of this study. However, GPC3 expression in healthy 
tissues in adult mammals is rarely observed and is, there-
fore, less likely to influence biodistribution of [89Zr]
Zr- N- suc- Df- ERY974.
In our study, we did not observe a reduction in HepG2 
xenograft uptake of [89Zr]Zr- N- suc- Df- ERY974 in the pres-
ence of an excess of unlabeled ERY974. This might be due 
to several reasons. First, high GPC3 expression of HepG2 
in vitro and ex vivo was observed, and might be too high 
to be blocked by excess of unlabeled ERY974 in vivo. In 
the TOV- 21G xenograft, which expresses lower levels of 
GPC3, an excess of unlabeled ERY974 was able to reduce 
tumor uptake of [89Zr]Zr- N- suc- Df- ERY974. Second, the 
monovalent character of ERY974 might be partial respon-
sible for the lack of reduction in HepG2 xenograft uptake 
on an excess of unlabeled ERY974. Adding an excess of 
bivalent GPC3 mAb namely reduced tumor- to- blood ratio. 
Furthermore circulating GPC3 protein shedded from 
the HepG2 tumor xenograft might redirect [89Zr]Zr- N- 
suc- Df- ERY974 to the liver and prevent tumor uptake. 
This phenomenon has been described for the epidermal 
growth factor receptor (EGFR) and an EGFR targeting 
mAb imgatuzumab. Shed EGFR in the circulation derived 
from the xenograft A431, that expresses high levels of 
EGFR, was able to redirect the 89Zr- labeled imgatuzumab 
to the liver at a low tracer protein dose.24 In that study, 
increasing the tracer protein dose led to a reduced liver 
and increased tumor uptake. Although we do not have 
data on the levels of circulating GPC3 protein in our study, 
in the presence of an excess of unlabeled ERY974 liver 
uptake of [89Zr]Zr- N- suc- Df- ERY974 was reduced. The cell 
line HepG2 has been shown to gradually increase secre-
tion of GPC3 protein up to 48 hours of in vitro culture.25 
In addition, concentration of GPC3 protein in serum has 
been described in patients with hepatocellular carcinoma 
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These data provide a rationale to study the biodistri-
bution and tumor targeting properties of [89Zr]Zr- N- 
suc- Df- ERY974 in a clinical trial to support ERY974 drug 
development.
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